52 related articles for article (PubMed ID: 27917627)
21. Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.
Chauhan P; Hu S; Prasad S; Sheng WS; Lokensgard JR
Glia; 2021 Apr; 69(4):858-871. PubMed ID: 33128485
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
23. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
24. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
25. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
26. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.
Xu R; Megati S; Roopchand V; Luckay A; Masood A; Garcia-Hand D; Rosati M; Weiner DB; Felber BK; Pavlakis GN; Sidhu MK; Eldridge JH; Egan MA
Vaccine; 2008 Sep; 26(37):4819-29. PubMed ID: 18657584
[TBL] [Abstract][Full Text] [Related]
27. Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.
Hosseini Rouzbahani N; Bayanolhagh S; Gholami M; Esmaeilzadeh A; Bayat Jozani Z; Mohraz M; Pourfathollah AA
Iran J Allergy Asthma Immunol; 2016 Oct; 15(5):403-412. PubMed ID: 27917627
[TBL] [Abstract][Full Text] [Related]
28. Novel adenovirus vector-based vaccines for HIV-1.
Barouch DH
Curr Opin HIV AIDS; 2010 Sep; 5(5):386-90. PubMed ID: 20978378
[TBL] [Abstract][Full Text] [Related]
29. Approaches to preventative and therapeutic HIV vaccines.
Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
[TBL] [Abstract][Full Text] [Related]
30. Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.
Chin'ombe N
Viruses; 2013 Aug; 5(9):2062-78. PubMed ID: 23989890
[TBL] [Abstract][Full Text] [Related]
31. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits.
Kardani K; Bolhassani A; Shahbazi S
Vaccine; 2016 Jan; 34(4):413-423. PubMed ID: 26691569
[TBL] [Abstract][Full Text] [Related]
32. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.
Yu TW; Chueh HY; Tsai CC; Lin CT; Qiu JT
Hum Vaccin Immunother; 2016 Dec; 12(12):3020-3028. PubMed ID: 27560197
[TBL] [Abstract][Full Text] [Related]
33. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system.
Sauter SL; Rahman A; Muralidhar G
Curr HIV Res; 2005 Apr; 3(2):157-81. PubMed ID: 15853721
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
